PIK3CA Mutation in Cancer
OncogenePhosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha
PIK3CA encodes the catalytic subunit of PI3K, a lipid kinase central to the PI3K/AKT/mTOR pathway. Mutations are frequent in breast, endometrial, and head and neck cancers.
What Is PIK3CA?
PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha) encodes the p110α catalytic subunit of phosphoinositide 3-kinase (PI3K), a lipid kinase central to the PI3K/AKT/mTOR signaling pathway. This pathway regulates cell growth, survival, metabolism, and motility. When PIK3CA is mutated, the PI3K enzyme becomes constitutively active, generating excessive PIP3 and driving uncontrolled AKT signaling.
PIK3CA Mutations in Cancer
PIK3CA is one of the most frequently mutated oncogenes across human cancers, altered in approximately 12-15% of all tumors. It is most prevalent in breast cancer (~35%, especially HR+/HER2- subtype), endometrial cancer (~50%), cervical cancer (~25%), and head and neck squamous cell carcinoma (~20%). The vast majority of mutations cluster at three hotspots: E545K and E542K in the helical domain, and H1047R in the kinase domain. These mutations have distinct biochemical mechanisms but all hyperactivate PI3K signaling.
Targeted Therapy and Clinical Significance
PIK3CA mutation status is a predictive biomarker for PI3K inhibitor therapy. Alpelisib (a PI3Kα-specific inhibitor) combined with fulvestrant is approved for PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer. Inavolisib, a next-generation PI3Kα inhibitor, has shown improved efficacy. PIK3CA mutations generally confer a relatively favorable prognosis in breast cancer but may be associated with resistance to certain endocrine therapies and anti-HER2 agents.
Morphological Associations
PIK3CA-mutant tumors tend to display distinct histological features: in breast cancer, they associate with lower-grade, well-differentiated tumors with lobular or tubular morphology. In endometrial cancer, PIK3CA mutations correlate with endometrioid histology. HistoAtlas quantifies these morphological differences computationally across all 33 TCGA cancer types, linking PIK3CA status to tissue-level changes detectable on H&E-stained whole slide images.
Frequently Asked Questions
What is a PIK3CA mutation?
A PIK3CA mutation is a change in the PIK3CA gene that causes the PI3K enzyme to be constitutively active, driving cell growth through the PI3K/AKT/mTOR pathway. PIK3CA is one of the most commonly mutated oncogenes, found in ~35% of breast cancers, ~50% of endometrial cancers, and subsets of many other tumor types.
What is PIK3CA mutation breast cancer?
PIK3CA mutations occur in approximately 35% of breast cancers, most commonly in hormone receptor-positive (HR+), HER2-negative subtypes. The three main hotspot mutations (E545K, E542K, H1047R) are targetable with PI3K inhibitors. Alpelisib plus fulvestrant is FDA-approved for PIK3CA-mutant, HR+/HER2- advanced breast cancer.
What is PIK3CA mutation treatment?
PIK3CA-mutant cancers can be treated with PI3K inhibitors. Alpelisib (Piqray) is approved for PIK3CA-mutant, HR+/HER2- advanced breast cancer in combination with fulvestrant. Inavolisib is a newer PI3K inhibitor under investigation. PIK3CA testing is now standard for advanced HR+/HER2- breast cancer patients.
What is PIK3CA mutation survival rate?
PIK3CA mutation impact on survival varies by cancer type and subtype. In HR+/HER2- breast cancer, PIK3CA mutations are generally associated with a relatively favorable prognosis but may predict resistance to certain therapies. HistoAtlas provides Kaplan-Meier survival curves comparing PIK3CA-mutant vs wild-type tumors across 33 TCGA cancer types.